{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:58:29Z","timestamp":1790359109044,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Among individuals with opioid use disorder using fentanyl, standard initial doses (2-4\u00a0mg) of buprenorphine may precipitate withdrawal, often preventing successful induction. Rapid low-dose induction is an emerging approach designed to mitigate this risk. This study describes a simplified rapid low-dose buprenorphine induction protocol in facilitating treatment initiation among patients presenting to an outpatient clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case series includes chart review data from nine patients with opioid use disorder treated at an outpatient substance use clinic who were initiated on buprenorphine-naloxone maintenance therapy. All had recent fentanyl use confirmed by UDS. Patients were instructed to follow a simplified induction protocol consisting of 1\u00a0mg of buprenorphine-naloxone, via 1\/8th of an 8\u2009\u2212\u20092\u00a0mg sublingual film, administered at home hourly for 8\u00a0h, followed by maintenance dosing of 8\u00a0mg twice daily. Patients were advised to wait at least 24\u00a0h since last fentanyl use prior to initiating the induction protocol. Successful induction was defined as being on maintenance treatment at a follow-up appointment one week later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the nine patients who began the rapid low-dose induction protocol, seven successfully transitioned to buprenorphine-naloxone maintenance by the 7-day follow-up. Two patients did not return for follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this case series, the simplified rapid low-dose buprenorphine induction protocol was well-tolerated and 77.8% of patients using fentanyl were able to successfully initiate buprenorphine-naloxone maintenance. Benefits of this protocol are use of a single, standard dose of buprenorphine-naloxone, rapid induction timeline over only 8\u00a0h, and simple patient instructions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00620-8","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:21:54Z","timestamp":1762424514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simplified rapid low-dose buprenorphine induction method for individuals using fentanyl: a case series"],"prefix":"10.1186","volume":"20","author":[{"given":"Ryan","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Woford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"1","key":"620_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","volume":"26","author":"ND Volkow","year":"2021","unstructured":"Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2021;26(1):218\u201333. https:\/\/doi.org\/10.1038\/s41380-020-0661-4.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"620_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","volume":"17","author":"HE Bird","year":"2023","unstructured":"Bird HE, Huhn AS, Dunn KE. Fentanyl Absorption, Distribution, Metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl. J Addict Med. 2023;17(5):503\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000001185","journal-title":"J Addict Med"},{"issue":"48","key":"620_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","volume":"73","author":"LJ Tanz","year":"2024","unstructured":"Tanz LJ, Stewart A, Gladden RM, Ko JY, Owens L, O\u2019Donnell J. Detection of illegally manufactured Fentanyls and carfentanil in drug overdose deaths - United States, 2021\u20132024. MMWR Morb Mortal Wkly Rep. 2024;73(48):1099\u2013105. Published 2024 Dec 5. https:\/\/doi.org\/10.15585\/mmwr.mm7348a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"620_CR4","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","volume":"118","author":"J Friedman","year":"2023","unstructured":"Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance Fentanyl overdose deaths in the United States, 2010\u20132021. Addiction. 2023;118(12):2477\u201385. https:\/\/doi.org\/10.1111\/add.16318","journal-title":"Addiction"},{"issue":"1","key":"620_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","volume":"30","author":"D Antoine","year":"2021","unstructured":"Antoine D, Huhn AS, Strain EC, et al. Method for successfully inducting individuals who use illicit Fentanyl onto Buprenorphine\/Naloxone. Am J Addict. 2021;30(1):83\u20137. https:\/\/doi.org\/10.1111\/ajad.13069.","journal-title":"Am J Addict"},{"issue":"4","key":"620_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","volume":"30","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine\/Naloxone: A review of the literature. Am J Addict. 2021;30(4):305\u201315. https:\/\/doi.org\/10.1111\/ajad.13135.","journal-title":"Am J Addict"},{"key":"620_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajem.2022.05.013","volume":"58","author":"A Spadaro","year":"2022","unstructured":"Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine precipitated opioid withdrawal: prevention and management in the ED setting. Am J Emerg Med. 2022;58:22\u20136. https:\/\/doi.org\/10.1016\/j.ajem.2022.05.013.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"620_CR8","doi-asserted-by":"publisher","first-page":"e2456253","DOI":"10.1001\/jamanetworkopen.2024.56253","volume":"8","author":"LW Suen","year":"2025","unstructured":"Suen LW, Chiang AY, Jones BLH, et al. Outpatient Low-Dose initiation of buprenorphine for people using Fentanyl. JAMA Netw Open. 2025;8(1):e2456253. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56253. Published 2025 Jan 2.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"620_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/ADM.0000000000000745","volume":"15","author":"MB Weimer","year":"2021","unstructured":"Weimer MB, Guerra M, Morrow G, Adams K. Hospital-based buprenorphine Micro-dose initiation. J Addict Med. 2021;15(3):255\u20137. https:\/\/doi.org\/10.1097\/ADM.0000000000000745.","journal-title":"J Addict Med"},{"issue":"5","key":"620_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/ADM.0000000000000961","volume":"16","author":"LW Suen","year":"2022","unstructured":"Suen LW, Lee TG, Silva M, et al. Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: A case series. J Addict Med. 2022;16(5):534\u201340. https:\/\/doi.org\/10.1097\/ADM.0000000000000961.","journal-title":"J Addict Med"},{"issue":"6","key":"620_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","volume":"60","author":"A Spadaro","year":"2022","unstructured":"Spadaro A, Sarker A, Hogg-Bremer W, et al. Reddit discussions about buprenorphine associated precipitated withdrawal in the era of Fentanyl. Clin Toxicol (Phila). 2022;60(6):694\u2013701. https:\/\/doi.org\/10.1080\/15563650.2022.2032730.","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"620_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","volume":"18","author":"S Wong","year":"2024","unstructured":"Wong S, Fabiano N, Webber D, Kleinman RA. High-Dose buprenorphine initiation: A scoping review. J Addict Med. 2024;18(4):349\u201359. https:\/\/doi.org\/10.1097\/ADM.0000000000001296.","journal-title":"J Addict Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00620-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:21:55Z","timestamp":1762424515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00620-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"McNabb Center IRB reviewed study proposal and this study was exempt from full IRB review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to proofread grammar and improve overall readability. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"Consent from individual patients was not obtained as no identifiable information is reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}